Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test
Introduction to MRD Monitoring
The Minimal Residual Disease (MRD) Monitoring for Multiple Myeloma Test is an advanced diagnostic tool that plays a pivotal role in the management of multiple myeloma, a type of blood cancer. This test is designed to detect the presence of residual cancer cells in patients who have undergone treatment, providing crucial information about the effectiveness of therapy and the likelihood of disease relapse.
What the Test Measures
This test utilizes flow cytometry to measure specific markers on the surface of myeloma cells, including:
- CD45
- CD19
- CD20
- CD27
- CD38
- CD138
- CD56
- CD117
- CD200
- CD81
- Kappa
- Lambda
By analyzing these markers, healthcare professionals can determine the presence of minimal residual disease, which is crucial for tailoring ongoing treatment strategies.
Who Should Consider This Test?
This test is recommended for patients diagnosed with multiple myeloma, particularly those who have completed initial treatment and are in remission. Individuals experiencing symptoms such as persistent fatigue, bone pain, or unexplained weight loss should also consider MRD monitoring. Additionally, patients with risk factors such as a history of aggressive disease or those undergoing anti-CD38 therapy should consult their oncologist regarding this test.
Benefits of Taking the Test
- Provides crucial data on treatment effectiveness.
- Helps in early detection of potential relapses.
- Guides oncologists in personalizing treatment plans.
- Enhances patient monitoring and management strategies.
Understanding Your Results
Results from the MRD monitoring test will indicate the levels of residual disease present. A lower level of residual disease suggests a better prognosis and may lead to adjustments in treatment. It is essential to discuss your results with your oncologist to understand the implications for your health and treatment plan.
Test Pricing
| Test Name | Discount Price (NGN) | Regular Price (NGN) |
|---|---|---|
| Minimal Residual Disease MRD Monitoring for Multiple Myeloma | 320,000 | 500,000 |
Booking Your Test
To book the Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test, please contact us at +2348077798758 or visit our website. Ensure you have the following information ready when booking:
- Sample time point (Chemotherapy time points)
- Previous diagnostic immunophenotype report
- Clinical history, especially if on anti-CD38 therapy
- Original TRF
- Date and time when the sample was drawn
- 1 or 2 unstained BMA smears made at the source
Don’t wait to understand your health better. Book your test today!
